Literature DB >> 20854925

N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.

Ayush Dagvadorj1, Shyh-Han Tan, Zhiyong Liao, Jianwu Xie, Martti Nurmi, Kalle Alanen, Hallgeir Rui, Tuomas Mirtti, Marja T Nevalainen.   

Abstract

Transcription factor Stat5a/b is critical for prostate cancer cell survival and for prostate xenograft tumor growth. In addition, the Stat5a/b signaling pathway may contribute to progression of organ-confined prostate cancer to castration-resistant and/or metastatic disease. Expression of nuclear Stat5a/b is clustered to high grade human prostate cancers, and nuclear Stat5a/b in primary prostate cancer predicts early disease recurrence after initial treatment. Here, we show by Western blotting and electromobility shift assay that Stat5a/b protein in human prostate cancer is N-terminally truncated. This short form of Stat5a/b is generated post-translationally in vivo in prostate cancer cells and is the predominant form of Stat5a/b that binds to DNA. We further demonstrate by mutagenesis and co-immunoprecipitations that the N-domain of Stat5a/b is required for binding to PIAS3, and that PIAS3 inhibits transcriptional activity of Stat5a/b in breast cancer cells but not in prostate cancer cells. Thus, the proteolytic cleavage of the N-terminus of Stat5a/b may be a mechanism by which Stat5 evades the transcriptional repression by PIAS3 in prostate cancer cells, and results in increased Stat5-driven gene expression and prostate cancer progression. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854925      PMCID: PMC2982800          DOI: 10.1016/j.biocel.2010.09.008

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  37 in total

1.  Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.

Authors:  Hongzhen Li; Ying Zhang; Andrew Glass; Tobias Zellweger; Edmund Gehan; Lukas Bubendorf; Edward P Gelmann; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 2.  PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription.

Authors:  J J Palvimo
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

Review 3.  Regulation of cytokine signaling pathways by PIAS proteins.

Authors:  Ke Shuai
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

4.  Generation of carboxy-terminally deleted forms of STAT5 during preparation of cell extracts.

Authors:  K Garimorth; T Welte; W Doppler
Journal:  Exp Cell Res       Date:  1999-01-10       Impact factor: 3.905

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  The significance of tetramerization in promoter recruitment by Stat5.

Authors:  S John; U Vinkemeier; E Soldaini; J E Darnell; W J Leonard
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

7.  Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.

Authors:  Ayush Dagvadorj; Robert A Kirken; Benjamin Leiby; James Karras; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.

Authors:  Ayush Dagvadorj; Sean Collins; Jean-Baptiste Jomain; Junaid Abdulghani; James Karras; Tobias Zellweger; Hongzhen Li; Martti Nurmi; Kalle Alanen; Tuomas Mirtti; Tapio Visakorpi; Lukas Bubendorf; Vincent Goffin; Marja T Nevalainen
Journal:  Endocrinology       Date:  2007-04-05       Impact factor: 4.736

9.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

10.  Purification and identification of the STAT5 protease in myeloid cells.

Authors:  Björn Schuster; Lisa Hendry; Helen Byers; Steven F Lynham; Malcolm A Ward; Susan John
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

View more
  10 in total

1.  Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Authors:  David T Hoang; Lei Gu; Zhiyong Liao; Feng Shen; Pooja G Talati; Mateusz Koptyra; Shyh-Han Tan; Elyse Ellsworth; Shilpa Gupta; Heather Montie; Ayush Dagvadorj; Saija Savolainen; Benjamin Leiby; Tuomas Mirtti; Diane E Merry; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-12-31       Impact factor: 6.261

2.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

3.  Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Authors:  Pooja G Talati; Lei Gu; Elyse M Ellsworth; Melanie A Girondo; Marco Trerotola; David T Hoang; Benjamin Leiby; Ayush Dagvadorj; Peter A McCue; Costas D Lallas; Edouard J Trabulsi; Leonard Gomella; Andrew E Aplin; Lucia Languino; Alessandro Fatatis; Hallgeir Rui; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2015-09       Impact factor: 4.307

Review 4.  Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.

Authors:  Lisa N Heppler; David A Frank
Journal:  Trends Cancer       Date:  2017-11-10

5.  Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.

Authors:  Lei Gu; Zhiyong Liao; David T Hoang; Ayush Dagvadorj; Shilpa Gupta; Shauna Blackmon; Elyse Ellsworth; Pooja Talati; Benjamin Leiby; Michael Zinda; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Dennis Huszar; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2013-08-13       Impact factor: 12.531

Review 6.  Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation.

Authors:  Olga A Timofeeva; Nadya I Tarasova
Journal:  JAKSTAT       Date:  2012-10-01

7.  Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.

Authors:  Axel Weber; Corina Borghouts; Christian Brendel; Richard Moriggl; Natalia Delis; Boris Brill; Vida Vafaizadeh; Bernd Groner
Journal:  Cancers (Basel)       Date:  2015-03-19       Impact factor: 6.639

Review 8.  Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.

Authors:  David T Hoang; Kenneth A Iczkowski; Deepak Kilari; William See; Marja T Nevalainen
Journal:  Oncotarget       Date:  2017-01-10

9.  A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer.

Authors:  Osama Hamzeh; Abedalrhman Alkhateeb; Julia Zhuoran Zheng; Srinath Kandalam; Crystal Leung; Govindaraja Atikukke; Dora Cavallo-Medved; Nallasivam Palanisamy; Luis Rueda
Journal:  Diagnostics (Basel)       Date:  2019-12-11

Review 10.  JAK/STAT pathway and molecular mechanism in bone remodeling.

Authors:  Eliana Rita Sanpaolo; Cinzia Rotondo; Daniela Cici; Ada Corrado; Francesco Paolo Cantatore
Journal:  Mol Biol Rep       Date:  2020-10-24       Impact factor: 2.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.